Note: This story was updated June 28, 2023, to correct the time frame of the ADAPT-SC+ clinical trial, in…
Marta Figueiredo, PhD
Editorial Associate Director of Resource Pages
Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology, and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — those that make up the lining of blood vessels — found in the umbilical cord of newborns. In addition to several research fellowships, she was awarded two Erasmus scholarships to conduct part of her studies in France. She has also authored several research papers published in peer-reviewed international scientific journals. Joana joined Bionews in 2018, starting as a science writer, then moving to a science editor position in 2020, and to editorial associate director of resource pages in 2025.
Education
- PhD, Biomedical Sciences, specialty of Molecular and Cellular Biology
- MSc, Evolutionary and Developmental Biology
- BSc, Biology, speciality Evolutionary and Developmental Biology
Certifications
- ICH Good Clinical Practice E6 (R2)
Published Works
- Non-canonical Wnt signaling regulates junctional mechanocoupling during angiogenic collective cell migration. eLife · 2019
- YAP and TAZ regulate adherens junction dynamics and endothelial cell distribution during vascular development. eLife · 2018
- Endothelial cell dynamics in vascular remodelling. Clinical Hemorheology and Microcirculation · 2016
Professional Accomplishments
- Awarded 2 Erasmus scholarships, several research fellowships, a scholarship conference award, and an honorable mention.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marta Figueiredo, PhD
Generalized myasthenia gravis (gMG) may be associated with a deficiency in a type of immune cell called myeloid-derived suppressor…
Descartes-08, Cartesian Therapeutics’ investigational CAR T-cell therapy, appears generally safe and markedly lessened symptom severity in the first five…
Both zilucoplan and rozanolixizumab, UCB’s experimental therapies for generalized myasthenia gravis (gMG), safely and effectively reduced symptom…
Myasthenia gravis (MG) patients with antibodies against the thyroid gland have significantly more B-cells — the immune cells that…
Fufang Huangqi decoction — a traditional Chinese medicine formula reported to reduce symptoms of myasthenia gravis (MG) — helps…
The dynamics of mitochondria — the cells’ powerhouses — and their associated energy metabolism are highly affected in people with…
Men with late-onset myasthenia gravis (MG) show poorer memory and spatial orientation, as well as lower-than-normal volumes of brain…
To celebrate Rare Disease Day, on Feb. 28, Janssen has launched a refreshed national campaign, called iMaGineMyMG, to increase…
Zilucoplan, UCB’s experimental therapy, safely and effectively eases symptom severity and improves the quality of life for adults with…